BofA raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $27 from $23 and keeps a Neutral rating on the shares. While “encouraged” by Q2 Daybue growth, the firm notes further acceleration is needed for upside from its current estimates and also awaits several key data readouts in the next 18 months to “understand the pipeline opportunity better,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP
- ACADIA Pharmaceuticals: Strong Financial Performance and Promising Outlook Justify Buy Rating
- ACADIA Pharmaceuticals: Balanced Outlook Amid Solid Performance and Future Uncertainties
- Acadia Pharmaceuticals Reports Strong Q2 2025 Growth
- ACADIA Pharmaceuticals: Strong Sales Performance and Growth Potential Drive Buy Rating